Phase 3 N=250 Reducing INfection at the Surgical SitE With Antibiotic Irrigation During Ventral Hernia Repair (RINSE Trial)
Ventral Hernia Repair
Primary: Surgical Site Infection — 11; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=116 Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging
Rheumatoid Arthritis
Primary: Arms 1 & 2: Assess Camera-specific Precision of TUV — 0.159; 0.067; 0.091; 0.124 Pixel intensity
N/A N=257 Financial Incentives for Smoking Cessation Among Disadvantaged Pregnant Women
Cigarette Smoking
Primary: 7-day Point Prevalence Abstinence Levels at Final Antepartum Assessment — 8; 31 Participants — p=<0.001
N/A N=21 C-Pulse IDE Feasibility Study- A Heart Assist System
Heart Failure
Primary: Number of Surviving Participants That Completed the Study — 3 Participants
Phase 2 N=10 Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Metastatic Breast Cancer · Breast Carcinoma · HER-2 Positive Breast Cancer
Primary: Maximum Tolerated Dose of Ruxolitinib in Combination With Trastuzumab (Phase I) — 25 milligrams
Phase 2 N=95 A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Primary Myelofibrosis · Anemia
Primary: The Number of Participants With Anemia Responses Over Any 84-Day Period During the Primary Treatment Period — 3; 2; 2; 10 Participants
N/A N=180 Early Initiation of Milk Expression in Mothers of Very Low Birth Weight Infants
Breast Milk Expression
Primary: Pumped Milk Volume Day 1 — 3; 4; 5 mL — p=0.015
Phase 3 N=406 Investigation of Novel Surgical Imaging for Tumor Excision
Breast Cancer
Primary: Percentage of Patients Who Had Residual Cancer Found in at Least One LUM Imaging System Guided Shave Among All Patients. — 7.6 percentage of participants
Phase 4 N=10 Examining the Effect of Burosumab on Muscle Function
X-linked Hypophosphatemia
Primary: Skeletal Muscle Adenosine Triphosphate (ATP) Synthesis Rate — 9.41 umol/g/min — p=0.4147
N/A N=44 Maximizing the Dietary Pattern of Older Adults: the Effects of Protein Intake on Protein Kinetics
Sarcopenia
Primary: Whole Body Protein Turnover — -0.16; -0.17; 0.48 g/kg lean body mass/day
Phase 3 N=32 Early Treatment of Cytokine Storm Syndrome in Covid-19
Cytokine Storm · COVID-19
Primary: Subjects Discharged From the Hospital Alive and Without the Need for Mechanical Ventilation. — 10; 10 Participants
Phase 3 N=239 Arimoclomol in Amyotropic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Combined Assessment of Function and Survival (CAFS) — 0.51; 0.49 score on a scale — p=0.6208
N/A N=32,771 Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial
Uterine Cervical Neoplasm · Uterine Neoplasms · Genital Neoplasms, Female
Primary: Screening Completion by Outreach Approach and Prior Screening Behavior — 3671; 3960; 1482; 3956 Participants — p=0.05
N/A N=26 Reaching and Engaging Depressed Senior Center Clients
Depression in Old Age
Primary: Number of Virtual ENGAGE-A Participants Who Attend Every Scheduled Therapy Session — 17 Participants
Phase 2 N=281 Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Cardiovascular Disease
Primary: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 — -66.91; -93.78; -97.53; -96.89 Percentage Change in Lp(a) — p=<0.001